News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
Wilmington, Del., August 15, 2023 -- Hyfe, Inc., the global leader in AI-powered cough detection, tracking and classification, announces today its partnership with ActiGraph, a leading provider of wearable digital health technology and scientific solutions for clinical drug development and academic research, to advance the use of AI-powered cough detection in clinical trials. Together, the companies are developing a new digital health tool to collect an unprecedented combination of data. Hyfe’s Acoustic AI technology will be integrated into the new FDA-cleared ActiGraph LEAP™ to detect cough frequency and pattern to reveal an in-depth view of an individual’s health, an advancement in clinical research for chronic cough, COPD, congestive heart failure, asthma, and the many other conditions for which cough is an important symptom.
The ActiGraph LEAP contains one of the industry’s most comprehensive and sophisticated collections of sensors that can continuously monitor sleep, mobility, heart rate and variability, oxygen saturation, blood pressure and skin temperature in a single fit-for-purpose device. The addition of Hyfe’s cough data tracking supports the development of much-needed novel digital endpoints for improved pharmaceutical interventions for cough.
We are thrilled to partner with ActiGraph and introduce our technology for integrating cough monitoring into their latest device. The existing methods of assessing cough in clinical trials are antiquated, and through this collaboration, we share a unified vision of revolutionizing this space with advanced digital measures.
Joe Brew
Co-founder and CEO of Hyfe
Cough is a widespread symptom with immense potential to reveal valuable insights about an individual’s health, but until now has been challenging to quantify in clinical trials. Hyfe’s AI-powered technology passively and remotely detects, timestamps, monitors, and reports the frequency and pattern of coughing, providing more data than ever before on the symptom. Hyfe recently announced its integration with remote patient monitoring platforms and the ActiGraph LEAP will be the first wearable device to utilize this capability and offer an even more comprehensive combination of data.
We are continuously looking for ways to advance the use of digital health technologies in clinical trials, and we are pleased to partner with the team at Hyfe to capture meaningful information about a key indicator of a patient's health: cough,” said Jeremy Wyatt, Chief Executive Officer of ActiGraph. “We see this as an incredibly valuable partnership that will give the clinical trial and pharmaceutical industries more comprehensive data than they’ve ever had before
Jeremy Wyatt
CEO of ActiGraph
The partnership is part of ActiGraph’s Accelerant™ program, designed to advance the use of digital health technologies in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams.
For more information, visit hyfe.com and theactigraph.com.
The partnership is part of ActiGraph’s Accelerant™ program, designed to advance the use of digital health technologies in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams.
About Hyfe
Hyfe, Inc. is the global leader in AI-powered cough detection and classification that provides insight into cough patterns and correlations and is being widely used to help patients gain a better understanding of their cough and have more informed conversations with their providers. With more than 700 million samples, Hyfe maintains the largest cough dataset in the world enabling the building of powerful models to track, manage and diagnose respiratory illnesses. Hyfe provides platforms and data for pharmaceutical companies, medical researchers, government agencies, health care providers and patients and has partnerships with leading academic institutions including Johns Hopkins University and the University of California at San Francisco. The company was founded in 2020 and is headquartered in Wilmington, Delaware. More information is available at hyfe.com, on social media @hyfeapp and LinkedIn at /hyfe.
Hyfe’s cough monitoring technology has not been cleared, approved, or authorized by the U.S. FDA.
About ActiGraph
ActiGraph is pioneering the digital transformation of clinical research. We provide end-to-end digital health technology (DHT) solutions by integrating and operationalizing the best hardware, software, and algorithms to generate reliable evidence and get the right treatments to the right patients, faster. ActiGraph’s medical-grade wearable technology platform has been used to capture real-world, continuous digital measures of activity, sleep, and mobility for nearly 250 industry-sponsored clinical trials and thousands of academic research studies. Appearing in over 22,000 published scientific papers to date, ActiGraph is the most experienced and trusted wearable technology partner in the industry. Learn more at theactigraph.com.
###
Contact:
press@hyfe.ai
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.